ARTA
TBPH icon

A.R.T. Advisors’s Theravance Biopharma TBPH Stock Holding History

A.R.T. Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22,290
Closed -$577K – 889
2019
Q4 		$577K Buy
22,290
+1,500
+7% +$29.1K 0.03% 786
2019
Q3 		$405K Buy
+20,790
New +$420K 0.02% 940
2019
Q1 		– Sell
-15,005
Closed -$384K – 1606
2018
Q4 		$384K Buy
15,005
+4,699
+46% +$127K 0.02% 828
2018
Q3 		$336K Sell
10,306
-3,255
-24% -$88.7K 0.02% 1002
2018
Q2 		$307K Buy
+13,561
New +$322K 0.01% 1100
2015
Q3 		– Sell
-53,379
Closed -$694K – 1581
2015
Q2 		$694K Buy
+53,379
New +$828K 0.02% 861
2015
Q1 		– Sell
-59,885
Closed -$893K – 1676
2014
Q4 		$893K Buy
+59,885
New +$1.04M 0.03% 697

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFS
Link Fund Solutions London, United Kingdom $157M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

A.R.T. Advisors's TBPH Position: Q1 2020 in Review

A.R.T. Advisors sold out of Theravance Biopharma (TBPH) in Q1 2020, closing a stake of 22,290 shares — an estimated $577K sold.

A.R.T. Advisors first reported a position in TBPH in Q4 2014 and held it in 7 quarters. The position peaked at $893K in Q4 2014. 105 funds tracked by Wall St. Rank hold TBPH as of Q1 2020.

  • A.R.T. Advisors reported no remaining Theravance Biopharma position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 22,290 Theravance Biopharma shares in Q1 2020, an estimated $577K.
  • A.R.T. Advisors first reported a position in Theravance Biopharma in Q4 2014 and held it in 7 quarters.
  • A.R.T. Advisors's Theravance Biopharma position peaked at $893K in Q4 2014.
  • 105 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.